NOV 002

a 1000-to-1 mixture of glutathione disulfide and cisplatin that is used to increase efficacy of chemotherapy against advanced non-small cell lung cancer; modulates cellular redox balance

Also Known As:

Networked: 6 relevant articles (4 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pazoles, Christopher J: 3 articles (05/2012 - 04/2008)
2.	Tew, Kenneth D: 3 articles (01/2010 - 04/2008)
3.	Townsend, Danyelle M: 3 articles (01/2010 - 04/2008)
4.	Cao, Lili: 1 article (04/2013)
5.	Gumireddy, Kiranmai: 1 article (04/2013)
6.	Huang, Qihong: 1 article (04/2013)
7.	Li, Anping: 1 article (04/2013)
8.	Liu, Lin: 1 article (04/2013)
9.	Pazoles, Christopher: 1 article (04/2013)
10.	Xu, Xiaowei: 1 article (04/2013)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2008 - "NOV-002 is a mechanistically novel agent with potential for ameliorating hematologic toxicity and enhancing efficacy when used in combination with standard chemotherapy to treat cancer patients." 02/01/2012 - "The addition of NOV-002 to chemotherapy has been shown to increase anti-tumor efficacy in animal models and some early phase oncology trials. " 05/01/2012 - "The oxidized glutathione mimetic NOV-002 is a unique anti-tumor agent that not only has the ability to inhibit tumor cell proliferation, survival, and invasion, but in some settings can also ameliorate cytotoxic chemotherapy-induced hematopoietic and immune suppression. " 01/01/2010 - "Previous and ongoing clinical studies demonstrate a significantly improved 1-year survival and decreased tumor progression rates in non-small cell lung (NSCLC) and ovarian cancer patients when NOV-002 was included in cisplatin containing regimens. " 04/30/2013 - "NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis."
2.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2010 - "Previous and ongoing clinical studies demonstrate a significantly improved 1-year survival and decreased tumor progression rates in non-small cell lung (NSCLC) and ovarian cancer patients when NOV-002 was included in cisplatin containing regimens. "
3.	Neoplasm Metastasis (Metastasis) 04/30/2013 - "Our results suggest that NOV-002 affects cell signaling pathways that are critical for invasion and metastasis and can potentially be effective in metastasis treatment in combination of other chemotherapies." 04/30/2013 - "NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis." 02/01/2012 - "NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and metastasis and enhances anti-tumor immune responsiveness in tumor models. " 04/30/2013 - "Here we report the oxidized glutathione small molecule compound NOV-002 reduces cancer cell invasion in vitro and metastasis in an animal model in combination with chemotherapy drug gemcitabine. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/15/2008 - "NOV-002 is a novel glutathione disulfide mimetic that when administered in combination with standard chemotherapeutic regimens has resulted in increased efficacy (survival, tumor response) and improved tolerance to chemotherapy (e.g., hematologic recovery) in advanced non-small cell lung cancer patients. "
5.	Breast Neoplasms (Breast Cancer) 02/01/2012 - "We evaluated the clinical effects of NOV-002 in primary breast cancer, whether adding NOV-002 to standard preoperative chemotherapy increased pathologic complete response rates (pCR) at surgery, and determined whether NOV-002 mitigated hematologic toxicities of chemotherapy and whether levels of myeloid derived suppressor cells (MDSC) were predictive of response. " 02/01/2012 - "Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer." 02/01/2012 - "Forty-one women with newly diagnosed stages II-IIIc HER-2 negative breast cancer received doxorubicin-cyclophosphamide followed by docetaxel (AC → T) every 3 weeks and concurrent daily NOV-002 injections. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Glutathione Disulfide (GSSG)
3.	Doxorubicin (Adriamycin)
4.	Cyclophosphamide (Cytoxan)
5.	Docetaxel (Taxotere)
6.	Gemcitabine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Neoadjuvant Therapy
3.	Injections